West Pharmaceutical Services (WST) earnings per share (EPS)

Earnings per share · fiscal 2025
$6.79

West Pharmaceutical Services (WST) reported diluted earnings per share of $6.79 in fiscal 2025 (the year ended December 31, 2025). That is 1.5% higher than the $6.69 of fiscal 2024. Figures as of 17 Nov 2026, 17:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings per share, fiscal 2025
$6.79
Change on fiscal 2024
+1.5%
Growth, 5 years
+8.2% a year
Growth, 10 years
+18.0% a year
Highest on record
$8.67fiscal 2021
Lowest on record
$0.95fiscal 2010
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

West Pharmaceutical Services earnings per share (EPS), in more detail

Over the five fiscal years to 2025 diluted earnings per share grew at a compound 8.2% a year; over ten years the rate was 18.0% a year. Across the 18 fiscal years on record (2008–2025), the highest was $8.67 in fiscal 2021 and the lowest $0.95 in fiscal 2010.

History · 18 fiscal years

Earnings per share by fiscal year

West Pharmaceutical Services earnings per share (EPS), year by year

West Pharmaceutical Services (WST) earnings per share (EPS) by fiscal year
Fiscal yearEarnings per shareChangeYear ended
2025$6.79 1.5% up
2024$6.69 15.1% down
2023$7.88 1.9% up
2022$7.73 10.8% down
2021$8.67 89.7% up
2020$4.57 42.4% up
2019$3.21 17.2% up
2018$2.74 37.7% up
2017$1.99 4.2% up
2016$1.91 46.9% up
2015$1.30 25.7% down
2014$1.75 11.5% up
2013$1.57 36.5% up
2012$1.15 6.5% up
2011$1.08 14.3% up
2010$0.95 10.8% down
2009$1.06 15.2% down
2008$1.25—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

How to read it

It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.

Earnings per share at health care companies of similar size

Earnings per share of West Pharmaceutical Services and comparable companies
CompanyEarnings per shareFiscal year
Labcorp Holdings LH$10.462025
Koninklijke Philips PHG€0.932025
West Pharmaceutical Services WST$6.792025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on WST

West Pharmaceutical Services, figure by figure

West Pharmaceutical Services (WST) overview: price, valuation and scorecardAll health care companies by market value

West Pharmaceutical Services earnings per share (EPS): questions and answers

What is West Pharmaceutical Services's diluted earnings per share?

West Pharmaceutical Services (WST) reported diluted earnings per share of $6.79 in fiscal 2025 (the year ended December 31, 2025). That is 1.5% higher than the $6.69 of fiscal 2024.

What is the growth rate of West Pharmaceutical Services's diluted earnings per share?

Over the five fiscal years to 2025 diluted earnings per share grew at a compound 8.2% a year; over ten years the rate was 18.0% a year.

What are the highest and lowest diluted earnings per share figures on record for West Pharmaceutical Services?

Across the 18 fiscal years on record (2008–2025), the highest was $8.67 in fiscal 2021 and the lowest $0.95 in fiscal 2010.

How is West Pharmaceutical Services's diluted earnings per share calculated?

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “West Pharmaceutical Services (WST) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/WST/eps

Underlying data: the company's filings with the SEC and Yahoo Finance.